Your browser doesn't support javascript.
loading
A Multielement Prognostic Nomogram Based on a Peripheral Blood Test, Conventional MRI and Clinical Factors for Glioblastoma.
Rao, Changjun; Jin, Jinghao; Lu, Jianglong; Wang, Chengde; Wu, Zerui; Zhu, Zhangzhang; Tu, Ming; Su, Zhipeng; Li, Qun.
Afiliação
  • Rao C; Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
  • Jin J; Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
  • Lu J; Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
  • Wang C; Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
  • Wu Z; Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
  • Zhu Z; Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
  • Tu M; Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
  • Su Z; Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
  • Li Q; Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
Front Neurol ; 13: 822735, 2022.
Article em En | MEDLINE | ID: mdl-35250826
ABSTRACT

BACKGROUND:

Glioblastoma (GBM) is one of the most malignant types of tumors in the central nervous system, and the 5-year survival remains low. Several studies have shown that preoperative peripheral blood tests and preoperative conventional Magnetic Resonance Imaging (MRI) examinations affect the prognosis of GBM patients. Therefore, it is necessary to construct a risk score based on a preoperative peripheral blood test and conventional MRI and develop a multielement prognostic nomogram for GBM.

METHODS:

This study retrospectively analyzed 131 GBM patients. Determination of the association between peripheral blood test variables and conventional MRI variables and prognosis was performed by univariate Cox regression. The nomogram model, which was internally validated using a cohort of 56 GBM patients, was constructed by multivariate Cox regression. RNA sequencing data from Gene Expression Omnibus (GEO) and Chinese Glioma Genome Atlas (CGGA datasets were used to determine peripheral blood test-related genes based on GBM prognosis.

RESULTS:

The constructed risk score included the neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), albumin/fibrinogen (AFR), platelet/lymphocyte ratio (PLR), and center point-to-ventricle distance (CPVD). A final nomogram was developed using factors associated with prognosis, including age, sex, the extent of tumor resection, IDH mutation status, radiotherapy status, chemotherapy status, and risk. The Area Under Curve (AUC) values of the receiver operating characteristic curve (ROC) curve were 0.876 (12-month ROC), 0.834 (24-month ROC) and 0.803 (36-month ROC) in the training set and 0.906 (12-month ROC), 0.800 (18-month ROC) and 0.776 (24-month ROC) in the validation set. In addition, vascular endothelial growth factor A (VEGFA) was closely associated with NLR and LMR and identified as the most central negative gene related to the immune microenvironment and influencing immune activities.

CONCLUSION:

The risk score was established as an independent predictor of GBM prognosis, and the nomogram model exhibit appropriate predictive power. In addition, VEGFA is the key peripheral blood test-related gene that is significantly associated with poor prognosis.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article